Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu Meguro

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Plos One|March 28, 2015
Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trialSeiji Sato, Yoshifumi Saisho, Kinsei Kou, et al.
Diabetology & Metabolic Syndrome|May 27, 2014
Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patientsMasami Tanaka, Risa Nishimura, Takeshi Nishimura, et al.
Clinical Drug Investigation|November 6, 2009
Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary careKen Yajima, Akira Shimada, Hiroshi Hirose, et al.
Internal Medicine (Tokyo, Japan)|April 19, 2011
Determinants of an optimal response to pioglitazone in terms of HDL-cholesterolYusuke Kabeya, Masuomi Tomita, Yoichiro Asai, et al.
Journal of Diabetes Investigation|January 28, 2022
Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case reportHironobu Sasaki, Arata Itoh, Yasuhiro Watanabe, et al.
Endocrine Journal|March 19, 2011
Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetesYoshifumi Saisho, Kinsei Kou, Kumiko Tanaka, et al.
Internal Medicine (Tokyo, Japan)|December 4, 2015
A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin TreatmentTakeshi Nishimura, Shu Meguro, Risa Sekioka, et al.
International Journal of Endocrinology|January 15, 2013
Factors Associated with the Decline of Kidney Function Differ among eGFR Strata in Subjects with Type 2 Diabetes MellitusShu Meguro, Masuomi Tomita, Yusuke Kabeya, et al.
Diabetes Research and Clinical Practice|March 22, 2015
C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetesTakeshi Nishimura, Shu Meguro, Risa Sekioka, et al.
Endocrinology|September 4, 2021
Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 PromoterAsuka Uto, Kazutoshi Miyashita, Sho Endo, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Plos One|March 28, 2015
Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trialSeiji Sato, Yoshifumi Saisho, Kinsei Kou, et al.
Diabetology & Metabolic Syndrome|May 27, 2014
Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patientsMasami Tanaka, Risa Nishimura, Takeshi Nishimura, et al.
Clinical Drug Investigation|November 6, 2009
Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary careKen Yajima, Akira Shimada, Hiroshi Hirose, et al.
Internal Medicine (Tokyo, Japan)|April 19, 2011
Determinants of an optimal response to pioglitazone in terms of HDL-cholesterolYusuke Kabeya, Masuomi Tomita, Yoichiro Asai, et al.
Journal of Diabetes Investigation|January 28, 2022
Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case reportHironobu Sasaki, Arata Itoh, Yasuhiro Watanabe, et al.
Endocrine Journal|March 19, 2011
Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetesYoshifumi Saisho, Kinsei Kou, Kumiko Tanaka, et al.
Internal Medicine (Tokyo, Japan)|December 4, 2015
A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin TreatmentTakeshi Nishimura, Shu Meguro, Risa Sekioka, et al.
International Journal of Endocrinology|January 15, 2013
Factors Associated with the Decline of Kidney Function Differ among eGFR Strata in Subjects with Type 2 Diabetes MellitusShu Meguro, Masuomi Tomita, Yusuke Kabeya, et al.
Diabetes Research and Clinical Practice|March 22, 2015
C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetesTakeshi Nishimura, Shu Meguro, Risa Sekioka, et al.
Endocrinology|September 4, 2021
Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 PromoterAsuka Uto, Kazutoshi Miyashita, Sho Endo, et al.
Pageof 6